Modulation of lincRNA-p21/mitomiR-181 and mitomiR-23b/SIRT1 signaling pathways in rotenone-induced neurodegeneration rat model

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss and α-synuclein-rich Lewy body accumulation. Mitochondrial dysfunction and microRNA (miRNA) dysregulation, particularly mitochondrial miRNAs (mitomiRs), are critical drivers of PD pathogenesis. This study investigated the neuroprotective efficacy of the SGLT2 inhibitor, dapagliflozin, against rotenone-induced neurotoxicity, focusing on the lincRNA-p21/mitomiR-181/PTEN and mitomiR-23b/SIRT1/AMPK signaling axes. Male Wistar rats were randomized into three groups: a control group, a PD model group received rotenone (2 mg/kg every 48 h, s.c.), and a treatment group received rotenone plus dapagliflozin (10 mg/kg/day, p.o.) for 28 days. In the inducted rotenone group lincRNA-p21 sponges mir-181 which leads to the upregulation of PTEN which inhibits the conversion of PIP2 to PIP3 thus downregulating AKT expression and subsequent activation of GSK-3β kinase enzyme which increases α-synuclein accumulation. In addition, the PD-control group showed upregulation of Mitomir-23b with subsequent downregulation of SIRT-1 expression and inactivation of LKB1. Accompanied by inhibition of AMPK phosphorylation which in turn prevents the degradation of accumulated α-synuclein. Dapagliflozin treatment upregulates mir-181 and downregulates mitomir-23b, which restores DJ-1 levels, which in turn activate the antioxidant genes HO-1 and PINK1, and improve mitochondrial function. Dapagliflozin exerts neuroprotection by restoring lincRNA-p21/mitomiR-181/PTEN and mitomiR-23b/SIRT1/AMPK homeostasis, thereby inhibiting α-synuclein proteotoxicity and mitigating oxidative stress and neuroinflammation.

Authors

Institutions

Publication Details

Journal
BMC Pharmacology and Toxicology
Published
2026-11-19
DOI
https://doi.org/10.1186/s40360-026-01192-2
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Modulation of lincRNA-p21/mitomiR-181 and mitomiR-23b/SIRT1 signaling pathways in rotenone-induced neurodegeneration rat model

Mai A. Zaafan, Youssef Labib, Amr M. Abdelhamid, Hazem M. Seoudi et al.
2 links
BMC Pharmacology and Toxicology
Parkinson's Disease Mechanisms and Treatments
article

Modulation of lincRNA-p21/mitomiR-181 and mitomiR-23b/SIRT1 signaling pathways in rotenone-induced neurodegeneration rat model

Mai A. Zaafan, Youssef Labib, Amr M. Abdelhamid, Hazem M. Seoudi, Menna M. Afify, Abdelrahman A. Zain-Elabdeen
article en

Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss and α-synuclein-rich Lewy body accumulation. Mitochondrial dysfunction and microRNA (miRNA) dysregulation, particularly mitochondrial miRNAs (mitomiRs), are critical drivers of PD pathogenesis. This study investigated the neuroprotective efficacy of the SGLT2 inhibitor, dapagliflozin, against rotenone-induced neurotoxicity, focusing on the lincRNA-p21/mitomiR-181/PTEN and mitomiR-23b/SIRT1/AMPK signaling axes. Male Wistar rats were randomized into three groups: a control group, a PD model group received rotenone (2 mg/kg every 48 h, s.c.), and a treatment group received rotenone plus dapagliflozin (10 mg/kg/day, p.o.) for 28 days. In the inducted rotenone group lincRNA-p21 sponges mir-181 which leads to the upregulation of PTEN which inhibits the conversion of PIP2 to PIP3 thus downregulating AKT expression and subsequent activation of GSK-3β kinase enzyme which increases α-synuclein accumulation. In addition, the PD-control group showed upregulation of Mitomir-23b with subsequent downregulation of SIRT-1 expression and inactivation of LKB1. Accompanied by inhibition of AMPK phosphorylation which in turn prevents the degradation of accumulated α-synuclein. Dapagliflozin treatment upregulates mir-181 and downregulates mitomir-23b, which restores DJ-1 levels, which in turn activate the antioxidant genes HO-1 and PINK1, and improve mitochondrial function. Dapagliflozin exerts neuroprotection by restoring lincRNA-p21/mitomiR-181/PTEN and mitomiR-23b/SIRT1/AMPK homeostasis, thereby inhibiting α-synuclein proteotoxicity and mitigating oxidative stress and neuroinflammation.

BMC Pharmacology and Toxicology
October University of Modern Sciences and Arts (EG)
Academy of Scientific Research and Technology, Cairo University, Faculty of Veterinary Medicine, Cairo University
Good health and well-being
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon